| Today’s Big NewsSep 8, 2023 |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today.
|
|
| By Kevin Dunleavy Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios. |
|
|
|
By Annalee Armstrong Verge Genomics is adding AstraZeneca to its Big Pharma AI collection with a $42 million upfront deal to find new targets for rare neurodegenerative diseases. |
By Conor Hale Paige plans to construct the “world’s largest” AI model trained on cancer images, built upon as many as 4 million biopsy samples. |
By Max Bayer,Gabrielle Masson Diagnostic giant Illumina has found a new top boss following a tumultuous last few months marked by the departure of CEO Francis DeSouza, with Jacob Thaysen, Ph.D., now set to take over. |
|
Thursday, September 14, 2023 | 11am ET / 8am PT Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. Join industry experts to learn about innovative strategies being used to unlock challenging targets. Register now.
|
|
By Fraiser Kansteiner After multiple lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book, the FTC is getting in on the action. |
By James Waldron The week after Otsuka Pharmaceutical made moves into the psychedelics space, the Japanese drugmaker has clinched a collaboration with Shape Therapeutics to develop intravitreally delivered adeno-associated viruses for ocular diseases. |
By Andrea Park In a move befitting its highland-dwelling namesake, Ibex Medical Analytics is building up a mountain of funding, which will help the tech developer expand the reach of its AI-powered cancer diagnostics. |
By Zoey Becker The nod comes after the agency initially declined to sign off on the drug due to uncertainties with Mounjaro's efficacy and cost-effectiveness. |
By Conor Hale Asensus plans to tap into Nvidia applications to augment its AI vision abilities, while it also looks to expand its robotics portfolio with an upcoming, next-generation platform known as Luna. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Andrea Park As it builds out a pipeline of digital therapeutics spanning a wide range of conditions—from smoking cessation to depression to schizophrenia—Click Therapeutics has made a habit of turning to the experts in those treatment areas for help. |
|
Thursday, September 21, 2023 | 2pm ET / 11am PT In today's ever-evolving healthcare landscape, understanding and leveraging data to develop comprehensive insights is crucial to stay ahead. Specialty datasets, such as genomics, clinical, labs, and patient hub data, are critical to unlock deeper insights and improve healthcare data utilization, and it’s important to ensure these various sources of data seamlessly integrate. Register now to learn more.
|
|
| Whitepaper Access this insightful whitepaper to explore the role collaboration platform technology can play in helping address current industry challenges and to generate business value. Sponsored by: Zoom |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
